为了观察程序性死亡1（PD-1）抑制剂在现实世界中的抗肿瘤疗效，并探讨NRS2002评分或其他临床特征与免疫治疗疗效之间的关系，我们回顾性分析了341名接受免疫检查点抑制剂（ICI）治疗的肿瘤患者。一个中心。本研究回顾性纳入2018年6月至2021年12月期间接受ICIs治疗的341例实体瘤患者。记录患者特征、ICI 反应和生存状态，并分析临床因素与生存之间的关系。所有患者的中位无进展生存期（PFS）为 5.8 个月，中位总生存期（OS）为 12.5 个月。根据单变量分析，体能状态 (PS)、NRS2002 评分、那不勒斯预后评分 (NPS)、淋巴细胞和 C 反应蛋白比率 (LCR)、治疗方案和营养支持与 PFS 或 OS 显着相关。无营养风险组 (NRS2002 0-2) 的中位 PFS 和 OS 显着优于有营养风险组 (NRS2002 ≥ 3)（PFS：HR = 1.82，95% CI 1.30-2.54，p 值 < .001； OS：HR = 2.49，95% CI 1.73-3.59，p 值 < .001）。 Cox 回归分析显示，NRS2002 评分是 PFS 和 OS 的独立预后因素。有营养风险组的客观缓解率（ORR）低于无营养风险组（分别为8.33%和19.71%，p值 = .037）。根据初始治疗时的 NRS2002 评分，处于营养风险的患者的预后比没有营养风险的患者更差。 NRS2002可作为预测免疫检查点抑制剂治疗疗效的初步指标。

To observe the antitumour efficacy of programmed death 1 (PD-1) inhibitors in the real world and explore the relationship between NRS2002 score or other clinical characteristics and immunotherapy efficacy, we retrospectively analyzed 341 tumor patients who received immune checkpoint inhibitor (ICI) treatment at one center. A total of 341 solid tumor patients treated with ICIs from June 2018 to December 2021 were retrospectively included in this study. Patient characteristics, ICI responses, and survival status were documented, and the relationships between clinical factors and survival were analyzed. Among all patients, the median progression-free survival (PFS) was 5.8 months, and the median overall survival (OS) was 12.5 months. The Performance Status (PS), NRS2002 score, The Naples Prognostic Score (NPS), Lymphocyte and C-reactive protein ratio (LCR), line of therapy, and nutritional support were significantly related to PFS or OS according to univariate analysis. The median PFS and OS were significantly better in the group without nutritional risk (NRS2002 0-2) than those with nutritional risk (NRS2002 ≥ 3) (PFS: HR = 1.82, 95% CI 1.30-2.54, p value < .001; OS: HR = 2.49, 95% CI 1.73-3.59, p value < .001). Cox regression analysis revealed that the NRS2002 score was an independent prognostic factor for both PFS and OS. The objective response rate (ORR) in the group at nutritional risk was lower than that in the group without nutritional risk (8.33% and 19.71%, respectively, p value = .037). Patients at nutritional risk according to the NRS2002 score at initial treatment had a poorer prognosis than those without nutritional risk. The NRS2002 could be used as a preliminary index to predict the efficacy of immune checkpoint inhibitor therapy.